MK-677 (Ibutamoren) Black / African Ancestry Dose Adjustments

What Is MK-677 and Why Does Ancestry Matter?

MK-677 (ibutamoren) is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile GH secretion and raises IGF-1 levels without suppressing endogenous GH feedback at typical doses. Murphy et al. Demonstrated in a placebo-controlled crossover study (N=32, elderly adults) that 25 mg/day MK-677 increased mean 24-hour GH pulsatility and raised serum IGF-1 by roughly 60% from baseline at steady state 1.

Ancestry shapes drug response through at least three mechanisms: pharmacokinetic variation (enzyme and transporter genetics), pharmacodynamic variation (receptor sensitivity and downstream signaling), and background disease prevalence that changes the risk-benefit calculation. These three pathways converge in ways that are clinically actionable even before ethnicity-stratified MK-677 trial data exist.

Why Ethnicity-Stratified MK-677 Data Are Sparse

MK-677 has been studied primarily in small trials of elderly white or mixed populations. A 2-year randomized controlled trial of MK-677 25 mg in older adults with hip fracture (N=292) reported no subgroup analysis by race 2. Pharmaceutical-grade development stalled after early cardiovascular safety signals in elderly populations, so large Phase 3 datasets with ethnicity stratification were never published.

Clinicians must therefore extrapolate from:

1. Population pharmacogenomic databases such as PharmGKB and gnomAD.
2. GH/IGF-1 physiology studies with ethnicity-stratified data.
3. Drug-interaction and comorbidity profiles enriched in African-ancestry populations.

The Regulatory Reality

MK-677 is not FDA-approved for any indication 3. It is purchased as a research compound or obtained through compounding pharmacies in some jurisdictions. The absence of an approved label means no package insert carries ancestry-specific dosing warnings. Every clinical decision in this space rests on mechanistic reasoning and indirect evidence.

GH/IGF-1 Axis Physiology in Black and African Ancestry Individuals

Baseline IGF-1 Differences

Several observational datasets show that Black Americans have modestly higher mean serum IGF-1 values compared with white Americans after adjustment for age, sex, and BMI. Data from the InCHIANTI study and NHANES subgroup analyses suggest differences of roughly 10 to 20 ng/mL at baseline 4. The Endocrine Society's 2011 growth hormone deficiency guideline acknowledges that "IGF-1 measurements must be interpreted relative to normative data derived from populations matched for age, sex, and ideally ethnicity" 5.

A higher baseline IGF-1 means that a fixed 25 mg MK-677 dose may push an African-ancestry patient further above the upper reference limit than it would a white patient starting from a lower baseline. Sustained IGF-1 above 300 ng/mL is associated with increased risk of acromegalic features, insulin resistance, and potentially elevated IGF-1-driven proliferative signaling 6.

Ghrelin Receptor Polymorphisms

The GHSR (ghrelin receptor) gene harbors functionally relevant polymorphisms. The Leu72Met variant (rs696217) and several promoter-region SNPs show differential allele frequencies across continental ancestry groups in gnomAD data 7. Variants that reduce GHSR constitutive activity could theoretically blunt MK-677 response at a given dose, though direct dose-response data in African-ancestry cohorts are not yet published. Clinicians should not assume reduced efficacy without monitoring; some individuals will show strong IGF-1 responses at 10 mg while others require 20 mg to reach target range.

Practical Implication

Start at 10 mg/day, draw IGF-1 and fasting glucose at 4 weeks, and titrate to 15 to 20 mg only if IGF-1 remains below 150 ng/mL and glucose is stable. Reserve 25 mg for patients who remain symptomatic (poor sleep quality, low lean mass accrual) and whose IGF-1 sits below 200 ng/mL at 20 mg.

Pharmacogenomics: CYP3A4, P-gp, and Hepatic Metabolism

CYP3A4 Activity by Ancestry

MK-677 is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp). CYP3A4 activity varies substantially across populations. Studies using midazolam as a phenotypic probe show that African-ancestry individuals carry a higher prevalence of the CYP3A4*1B allele (rs2740574), which may alter transcriptional regulation of CYP3A4 8. The clinical direction of CYP3A4*1B is debated: some in vitro data suggest modestly increased expression while others show no functional difference versus *1 9.

A second variant, CYP3A4*22 (rs35599367), reduces enzyme activity and is found in roughly 5 to 7% of Europeans but is rare in African-ancestry populations, meaning this particular slow-metabolizer risk is lower in this group. The net pharmacokinetic effect on MK-677 plasma exposure in African-ancestry patients is therefore uncertain rather than predictably high or low.

ABCB1 (P-gp) Variants

Several ABCB1 SNPs (rs1045642, rs2032582) show population-frequency differences in gnomAD across ancestries 10. P-gp limits intestinal absorption of MK-677. Higher P-gp activity could reduce oral bioavailability; lower activity could raise it. Without prospective pharmacokinetic data in African-ancestry cohorts, this remains a theoretical variable that argues for biomarker-guided titration rather than empiric high-dose initiation.

Drug-Drug Interactions to Check First

Patients of African ancestry are more likely to be prescribed CYP3A4-relevant medications because of higher rates of hypertension and its sequelae. Calcium channel blockers (amlodipine, diltiazem) inhibit CYP3A4, which could raise MK-677 exposure. Rifampicin, occasionally prescribed for latent TB, is a potent CYP3A4 inducer that could reduce MK-677 levels by 50% or more 11. Review the full medication list before initiating.

Hypertension, Fluid Retention, and Cardiovascular Risk

Background Prevalence

Hypertension affects approximately 55% of non-Hispanic Black adults in the United States compared with 46% of non-Hispanic white adults, based on 2017 to 2020 NHANES data reported by the CDC 12. Black adults also develop hypertension roughly a decade earlier on average and sustain higher rates of left ventricular hypertrophy and stroke.

MK-677 causes sodium and water retention, particularly in the first 4 to 8 weeks of use, through IGF-1-mediated renal tubular sodium reabsorption. Murphy et al. 1 noted edema in a subset of participants at 25 mg. In an elderly hip-fracture population, MK-677 was associated with increased rates of congestive heart failure (CHF) compared with placebo 2.

Antihypertensive Interactions

ACE inhibitors and ARBs are considered less effective as monotherapy in Black patients with hypertension according to the ACC/AHA 2017 guideline, which recommends thiazide diuretics or calcium channel blockers as first-line agents 13. Thiazide diuretics partially counteract MK-677-induced fluid retention, which may be beneficial; however, thiazides also impair glucose tolerance, compounding MK-677's own insulin-resistance effect. Clinicians should monitor fasting glucose or HbA1c at baseline and at 4 and 12 weeks.

Blood Pressure Monitoring Schedule

Patients with pre-existing hypertension or BMI above 30 should have blood pressure checked at:

• Baseline
• 2 weeks after initiation
• 4 weeks after initiation
• Every 12 weeks thereafter

Any sustained increase in systolic BP of more than 10 mmHg warrants dose reduction or treatment pause.

Chronic Kidney Disease and Renal Safety

Elevated ESKD Risk in Black Adults

Black Americans develop end-stage kidney disease (ESKD) at roughly 3 times the rate of white Americans, a disparity driven by higher hypertension prevalence, higher type 2 diabetes prevalence, and the APOL1 G1/G2 risk alleles carried by approximately 13% of African Americans 14. APOL1 high-risk genotypes (two copies of G1 or G2) accelerate CKD progression independently of other risk factors.

MK-677 has not been studied in patients with CKD stage 3 or higher. IGF-1 plays a complex role in renal physiology: physiologic levels support glomerular filtration, but supraphysiologic levels in acromegaly are associated with glomerulomegaly and proteinuria 15.

Dose Caps by eGFR

Given this mechanistic concern and the lack of safety data, a reasonable clinical framework is:

| eGFR (mL/min/1.73 m²) | Suggested MK-677 maximum dose | |---|---| | Above 60 | 20 mg/day with monitoring | | 45 to 60 | 10 mg/day; check urine albumin/creatinine ratio every 12 weeks | | 30 to 44 | Defer MK-677; insufficient safety data | | Below 30 | Contraindicate pending clinical evidence |

Screen for APOL1 risk genotype if ancestry suggests West or Central African heritage and CKD is present or suspected. This is now available through several commercial pharmacogenomic panels.

G6PD Deficiency Considerations

Prevalence and Mechanism

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited enzyme disorder globally. Allele frequency in males of African ancestry ranges from approximately 10 to 14% depending on the specific sub-population studied, with the A- variant (c.202G>A; c.376A>G) predominating 16.

G6PD deficiency impairs the hexose monophosphate shunt, reducing NADPH production and leaving red blood cells vulnerable to oxidative damage. MK-677's direct risk for hemolysis in G6PD-deficient patients has not been studied. However, MK-677 increases GH-driven lipolysis and mitochondrial oxidative metabolism, potentially raising reactive oxygen species (ROS) production 17.

Clinical Guidance

Screen for G6PD deficiency before initiating MK-677 in males of African ancestry when G6PD status is unknown. G6PD-deficient patients started on MK-677 should have a complete blood count with reticulocyte count at 4 and 8 weeks. Any drop in hemoglobin exceeding 1.5 g/dL from baseline warrants immediate discontinuation and hematology referral.

Insulin Resistance and Glucose Monitoring

MK-677 reliably worsens insulin sensitivity. In the Murphy et al. Trial, fasting glucose rose from a mean of 91 mg/dL to 98 mg/dL at steady state on 25 mg/day 1. This effect is dose-dependent. Black adults in the US have higher age-adjusted rates of type 2 diabetes (approximately 12.1% versus 7.4% in non-Hispanic white adults) per ADA data 18.

Pre-diabetic patients (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) face a meaningful risk of crossing into overt diabetes on 25 mg MK-677. The 10 mg starting dose produces a smaller IGF-1 and GH response and, mechanistically, a smaller insulin-antagonist effect. HbA1c should be checked at baseline and every 3 months in patients with any metabolic risk factor.

Dosing Protocol Summary

Step-by-Step Initiation

1. Pre-initiation labs: IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel (eGFR, electrolytes), CBC, and blood pressure measurement. Consider G6PD screening in males.
2. Start dose: 10 mg MK-677 orally at bedtime.
3. Week 4 check: IGF-1, fasting glucose, blood pressure, body weight (fluid check).
4. Titration decision:
   • IGF-1 <150 ng/mL and glucose stable: increase to 15 mg.
   • IGF-1 150 to 250 ng/mL: continue 10 mg, recheck at week 8.
   • IGF-1 >300 ng/mL: reduce to 5 mg or pause.
5. Week 12 check: Full lab panel plus urine albumin/creatinine ratio.
6. Maximum recommended dose for this population: 20 mg/day unless IGF-1 data justify higher and renal/metabolic risk factors are absent.

Signs That Warrant Dose Reduction

Pitting edema at the ankles, systolic BP rise exceeding 10 mmHg from baseline, fasting glucose exceeding 126 mg/dL, or IGF-1 above 300 ng/mL on two consecutive measurements all warrant dose reduction. Do not simply add a diuretic to manage edema without re-assessing the MK-677 dose first.

Prescriber Checklist Before Initiating MK-677 in Black / African Ancestry Patients

• Confirm investigational-use context and document informed consent regarding non-FDA-approved status.
• Obtain IGF-1, fasting glucose, HbA1c, CMP, CBC, and urine ACR.
• Screen G6PD status in males.
• Review concomitant medications for CYP3A4 inhibitors or inducers.
• Assess APOL1 genotype if CKD is present or family history suggests high-risk nephropathy.
• Document baseline blood pressure and target BP range.
• Schedule 4-week and 12-week follow-up labs before writing the first prescription.